Core Viewpoint - Jiangsu Hualan Pharmaceutical Materials Co., Ltd. plans to establish a wholly-owned subsidiary in Hainan Province with an investment of 50 million RMB, focusing on pharmaceutical production and technology research [2] Company Overview - Hualan Co. was established on June 4, 1992, with a registered capital of 1,642.01624 million RMB, and is primarily engaged in the R&D, production, and sales of packaging materials for injectable drugs [2] - The company has four subsidiaries, including Chongqing Fuling Sanhai Lanling Co., Ltd. and Jiangsu Hualan Dangseng Biotechnology Co., Ltd. [2] Financial Performance - The company's revenue for 2022, 2023, 2024, and the first three quarters of 2025 were 584 million RMB, 623 million RMB, 586 million RMB, and 441 million RMB, reflecting year-on-year changes of -28.84%, 6.64%, -5.86%, and 4.36% respectively [3] - The net profit attributable to the parent company for the same periods was 93.75 million RMB, 118 million RMB, 49.57 million RMB, and 53.32 million RMB, with year-on-year growth rates of -56.60%, 25.79%, -57.96%, and 2.06% respectively [3] - The company's asset-liability ratios for the same periods were 6.36%, 8.31%, 10.22%, and 13.48% [3]
华兰股份投资设立全资子公司已完成工商登记